Transcutaneous oxygen tension (TcpO2) at rest, sensitized by oxygen inhalation tests, is widely applied for the evaluation of chronic critical limb ischemia (CLI). If foot TcpO2 measurements are good prognostic factors of the risk of amputation or the probability of wound healing without amputation, they have never proven their hability to estimate the risk of death in patients with critical limb ischemia. On the one hand, studies have considered only the response observed on legs without considered the thoracic variations. On the other hand, the variability of the TcpO2 signal has never been analyzed as a prognostic factor. The objective of the NOVICE study is therefore to assess, first, whether the variability of resting TcPO2 values at thoracic probe as well as at affected limb probe is a morbidity-mortality prognostic factor and secondly, to evaluate during the oxygen tests, if the measurement of the amplitude of the distal responses in ischemic zone compared to the response observed in thoracic probe is a prognostic factor of morbi-mortality.
This is an ambispective (both retrospective and prospective) cohort study in which any major patient, referred for resting (transcutyaneous oxygen pressure = TcpO2) for suspicion of critical limb ischemia, is included retrospectively and prospectively from November 2018 to October 2020. Tcpo2 recording are analysed to determine specific parameters (signal variability and response top oxygen). A morbidity-mortality follow-up is carried out between 12 and 15 months after the Tcpo2 measurement. A Kaplan Mayer study of these indices against MALE (major adverse lower limb events ) and MACE(Major adverse cardiovascular events) will be carried out.
Study Type
OBSERVATIONAL
Enrollment
300
Analysis of transcutaneous oximetry (Tcpo2) in terme of variability at rest and of response to oxygen inhalation
Centre hospitalier universitaire
Angers, France
Mortality
presence of MACE (major adverse cardiovascular event) following the oximetry test
Time frame: 12 months
Morbidity
presence of MALE (major adverse lower limb event) following the oximetry test
Time frame: 12 moths
Mortality (intermediate analysis)
Mortality all causes (intermediate analysis prior to Covid interference)
Time frame: 6 months minimal follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.